Schering takes Primovist MRI (magnetic resonance imaging) liver agent to Sweden:
This article was originally published in Clinica
Executive Summary
Schering has moved a step closer to selling its MRI-based liver contrast agent throughout Europe, after gaining market approval for the product in Sweden. Primovist is a gadolinium-based contrast medium that is specifically taken up by liver cells. It is designed to simultaneously detect, locate and distinguish various types of liver lesions, including liver tumours, metastases and other malignant and benign lesions. Based on the Swedish registration, the Berlin, Germany company said it would start a mutual recognition procedure for the EU, with Sweden acting as reference member state. EU registration is expected in most countries within 2004, the firm predicted. Submissions for approval in Japan and other Asian countries, where liver examinations are particularly frequent, are also planned to take place this year.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.